December 12, 2018
Astellas Pharma said on December 11 that it has launched its FLT3 inhibitor Xospata (gilteritinib) in the US for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an FTL3 mutation as detected by an...read more